Translational research in hepatic encephalopathy: New diagnostic possibilities and new therapeutic approaches

Marta Llansola, Carmina Montoliu, Ana Agusti, Vicente Hernandez-Rabaza, Andrea Cabrera-Pastor, Michele Malaguarnera, Belen Gomez-Gimenez, Alma Orts, Raquel Garcia-Garcia, Tiziano Balzano, Lucas Taoro, Vicente Felipo
2014 European Journal of Molecular and Clinical Medicine  
Chronic liver disease (e.g. cirrhosis) affects brain function. There is a high incidence of mild cognitive impairment and psychomotor slowing in patients with cirrhosis. This condition, known as minimal hepatic encephalopathy (MHE) affects more than 2 million people in the European Union and has serious health, social and economic consequences. There are no effective treatments for MHE. Rat models of MHE reproduce cognitive and motor alterations seen in patients, showing reduced performance in
more » ... ced performance in different types of cognitive tests, including learning a conditional discrimination task in a Y maze. Reduced ability to learn the Y maze task is due to reduced function of the glutamate-nitric oxide (NO)-cGMP pathway in cerebellum, assessed in vivo by microdialysis. This results in reduced formation of cGMP in response to activation of NMDA receptors and impairment of learning ability. Both hyperammonemia and neuroinflammation contribute to impair this pathway. The effect is mediated by enhanced tonic activation of NMDA and GABA A receptors and of MAP-kinase p38. Based on these mechanistic studies new therapeutic strategies acting on specific targets in the brain have been designed and tested, which have successfully restored the function of the glutamate-NO-cGMP pathway in vivo and learning ability in rats with MHE. This can be achieved by therapeutic treatments using: a) phosphodiesterase 5 inhibitors (sildenafil, zaprinast), that increase cGMP levels by reducing its degradation b) extracellular cGMP c) antagonists of type A GABA receptors (bicuculline) d) neurosteroids that modulate GABAergic tone (pregnenolone sulfate) e) inhibitors of cyclooxygenase (ibuprofen) which reduce neuroinflammation f) inhibitors of MAP-kinase p38 (SB239063), that reduce microglial activation and neuroinflammation New Horizons in Translational Medicine http://dx.
doi:10.1016/j.nhtm.2014.11.057 fatcat:uz2bq3545reezpynbvefp565ru